The FDA’s recent BLA approval of Tecelra (afamitresgene autoleucel) signifies a pivotal advancement in cell therapy, specifically for metastatic or unresectable synovial sarcoma. As the first T cell receptor (TCR) cell therapy approved for solid tumors, Tecelra offers renewed hope to patients with limited options. Tecelra, a genetically modified autologous T cell therapy targeting melanoma-associated … Continue reading Tecelra: A Breakthrough in Engineered T Cell Therapy for Solid Tumors